研究报告 |
|
|
|
|
组合型嵌合抗原受体的构建及分析鉴定* |
林海英**(),姚玢妍,于艺洁,杨扬 |
福州大学生物科学与工程学院 药物生物技术研究所 福州 350108 |
|
Construction, Analysis and Characterization of Combinvssatorial Chimeric Antigen Receptor |
LIN Hai-ying**(),YAO Bin-yan,YU Yi-jie,YANG Yang |
Medicine Biotechnology and Engineering Research Institute,College of Biological Science and Technology, Fuzhou University,Fuzhou 350108,China |
引用本文:
林海英, 姚玢妍, 于艺洁, 杨扬. 组合型嵌合抗原受体的构建及分析鉴定*[J]. 中国生物工程杂志, 2023, 43(6): 12-19.
LIN Hai-ying, YAO Bin-yan, YU Yi-jie, YANG Yang. Construction, Analysis and Characterization of Combinvssatorial Chimeric Antigen Receptor. China Biotechnology, 2023, 43(6): 12-19.
链接本文:
https://manu60.magtech.com.cn/biotech/CN/10.13523/j.cb.2211060
或
https://manu60.magtech.com.cn/biotech/CN/Y2023/V43/I6/12
|
[1] |
Ramos C A, Dotti G. Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy. Expert Opinion on Biological Therapy, 2011, 11(7): 855-873.
doi: 10.1517/14712598.2011.573476
|
[2] |
Deepak R, Maria N, Irene G, et al. CEACAM7 is an effective target for CAR T-cell therapy of pancreatic ductal adenocarcinoma. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research, 2021, 27(5): 1538-1552.
doi: 10.1158/1078-0432.CCR-19-2163
|
[3] |
Vitanza N A, Johnson A J, Wilson A L, et al. Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis. Nature Medicine, 2021, 27(9): 1544-1552.
doi: 10.1038/s41591-021-01404-8
pmid: 34253928
|
[4] |
Majzner R G, Ramakrishna S, Yeom K W, et al. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature, 2022, 603(7903): 934-941.
doi: 10.1038/s41586-022-04489-4
|
[5] |
Guo Y L, Feng K, Liu Y, et al. Phase I study of chimeric antigen receptor-modified T cells in patients with EGFR-positive advanced biliary tract cancers. Clinical Cancer Research, 2017, 24: 1277-1286.
doi: 10.1158/1078-0432.CCR-17-0432
|
[6] |
Shi D, Shi Y, Kaseb A O, et al. Chimeric antigen receptor-glypican-3 T-cell therapy for advanced hepatocellular carcinoma: results of phase I trials. Clin Cancer Res, 2020, 26(15):3979-3989.
doi: 10.1158/1078-0432.CCR-19-3259
pmid: 32371538
|
[7] |
Kowolik C M, Topp M S, Gonzalez S, et al. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Research, 2006, 66(22): 10995-11004.
doi: 10.1158/0008-5472.CAN-06-0160
|
[8] |
Wilkie S, van Schalkwyk M C I, Hobbs S, et al. Dual targeting of ErbB2 and MUC 1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. Journal of Clinical Immunology, 2012, 32(5): 1059-1070.
doi: 10.1007/s10875-012-9689-9
pmid: 22526592
|
[9] |
郑乃溶, 徐建青. CAR-T细胞免疫疗法的研究进展. 复旦学报(医学版), 2022, 49(2): 295-299.
|
|
Zheng N R, Xu J Q. Research progress of CAR-T cell immunotherapy. Fudan University Journal of Medical Sciences, 2022, 49(2): 295-299.
|
[10] |
Jiang Z, Jiang X, Chen S, et al. Anti-GPC3-CAR T cells suppress the growth of tumor cells in patient-derived xenografts of hepatocellular carcinoma. Front Immunol, 2016, 7: 690.
doi: 10.3389/fimmu.2016.00690
pmid: 28123387
|
[11] |
Jindal V, Arora E, Gupta S. Challenges and prospects of chimeric antigen receptor T cell therapy in solid tumors. Medical Oncology, 2018, 35(6): 87.
doi: 10.1007/s12032-018-1149-9
pmid: 29730801
|
[12] |
Yu S N, Li A P, Liu Q, et al. Chimeric antigen receptor T cells: a novel therapy for solid tumors. Journal of Hematology & Oncology, 2017, 10(1): 1-13.
|
[13] |
Kloss C C, Condomines M, Cartellieri M, et al. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nature Biotechnology, 2013, 31(1): 71-75.
doi: 10.1038/nbt.2459
pmid: 23242161
|
[14] |
Llovet J M, Chen Y B, Wurmbach E, et al. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology, 2006, 131(6): 1758-1767.
doi: 10.1053/j.gastro.2006.09.014
pmid: 17087938
|
[15] |
Zhu Z W. Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut, 2001, 48(4): 558-564.
doi: 10.1136/gut.48.4.558
pmid: 11247902
|
[16] |
Baumhoer D, Tornillo L, Stadlmann S, et al. Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4, 387 tissue samples. American Journal of Clinical Pathology, 2008, 129(6): 899-906.
doi: 10.1309/HCQWPWD50XHD2DW6
pmid: 18480006
|
[17] |
Gao H, Li K, Tu H, et al. Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma. Clinical Cancer Research, 2014, 20(24):6418-6428.
doi: 10.1158/1078-0432.CCR-14-1170
pmid: 25320357
|
[18] |
Liu Y, Li P K, Li C L, et al. Inhibition of STAT3 signaling blocks the anti-apoptotic activity of IL-6 in human liver cancer cells. Journal of Biological Chemistry, 2010, 285(35): 27429-27439.
doi: 10.1074/jbc.M110.142752
pmid: 20562100
|
[19] |
Went P T H, Lugli A, Meier S, et al. Frequent EpCam protein expression in human carcinomas. Human Pathology, 2004, 35(1): 122-128.
doi: 10.1016/j.humpath.2003.08.026
pmid: 14745734
|
[20] |
Deng Z L, Wu Y H, Ma W B, et al. Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM. BMC Immunology, 2015, 16(1): 1-9.
doi: 10.1186/s12865-014-0064-x
|
[21] |
Zhang B L, Li D, Gong Y L, et al. Preclinical evaluation of chimeric antigen receptor-modified T cells specific to epithelial cell adhesion molecule for treating colorectal cancer. Hum Gene Ther, 2019, 30(4):402-412.
doi: 10.1089/hum.2018.229
|
[22] |
Yan T, Zhu L F, Chen J. Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment. Experimental Hematology & Oncology, 2023, 12(1): 1-18.
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|